

1 SUPPLEMENTARY MATERIAL

2

3 Studying the regression profiles of  
4 cervical tumours during radiotherapy  
5 treatment using a patient-specific  
6 multiscale model.

---

7 Christos A. Kyroudis<sup>1</sup>, Dimitra D. Dionysiou<sup>1</sup>, Eleni A. Kolokotroni<sup>1</sup>, Georgios S. Stamatakos<sup>1</sup>

8 <sup>1</sup>In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer  
9 Systems, School of Electrical and Computer Engineering, National Technical University of  
10 Athens, Athens, Greece

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## SUPPLEMENTARY MATERIAL SECTION SA

### BRACHYTHERAPY TREATMENT MODELLING

**(Derivation of the equation used within CERONCO to compute the survival fraction after each successive PDR pulse).**

The basis of tumour response to brachytherapy treatment modeling is the modified Linear Quadratic model with correction for incomplete repair of Pulsed Dose Rate Brachytherapy (1),(2),(3). Considering a fraction of pulsed brachytherapy consisting of N pulses of dose d and an inter-pulse interval of the order of one hour, sub-lethal damage may not completely be repaired and the final cell survival fraction is given by:

$$SF_N(d) = \exp[-(\alpha Nd + \beta N G_N d^2)] \quad (S1)$$

where  $G_N$ , the Lea and Catcheside factor, is calculated from the temporal characteristics of the dose distribution. Equation (S1) assumes monoexponential repair kinetics of the beta component of radiation damage (see equation S6 below). Several studies addressing the issue of G Factor calculation for pulsed brachytherapy can be found in literature. The following equations have been used for the calculation (2), (4):

$$G_N(PDR) = \frac{2}{\mu t} \left[ 1 - \frac{NY-S^2}{N\mu t} \right] \quad (S2)$$

$$Y = 1 - e^{-\mu t} \quad (S3)$$

$$S = \frac{NK - K - NK^2 e^{-\mu t} + K^{N+1} e^{-\mu Nt}}{(1 - K e^{-\mu t})^2} \quad (S4)$$

$$K = e^{-\mu x} \quad (S5)$$

$$\mu = \frac{\ln}{T_{1/2}} \quad (S6)$$

where:

56 t is the duration of each pulse,

57 x is the time between pulses without irradiation,

58  $\mu$  is the repair rate constant,

59 and  $T_{1/2}$  is the half time for sub-lethal damage repair. Monoexponential recovery kinetics is assumed.

60

61 In order to simulate within CERONCO, where a time step of one hour is used, the number of cells that  
62 are lethally hit by each successive pulse the following consideration has been made:

63 Let  $P_{init}$  be the initial tumour cell population. According to the modified LQ model, after N pulses of  
64 dose d have been applied the remaining (survived) tumour cell population will be:

$$65 \quad P_N = P_{init} SF_N = P_{init} \exp(-\alpha Nd - \beta NG_N d^2) \quad (S7)$$

66 The number of surviving tumour cells just after each successive pulse in the N-pulse scheme is given  
67 by:

$$P_1 = P_{init} \exp(-\alpha d - \beta G_1 d^2)$$

$$68 \quad P_2 = P_{init} \exp(-\alpha 2d - 2\beta G_2 d^2)$$

$$69 \quad P_3 = P_{init} \exp(-\alpha 3d - 3\beta G_3 d^2)$$

70 ...

$$71 \quad P_{N-2} = P_{init} \exp(-\alpha(N-2)d - (N-2)\beta G_{N-2} d^2)$$

$$72 \quad P_{N-1} = P_{init} \exp(-\alpha(N-1)d - (N-1)\beta G_{N-1} d^2)$$

$$73 \quad P_N = P_{init} \exp(-\alpha Nd - \beta NG_N d^2)$$

74 Since each pulse acts upon the tumour cell population that remained alive after all previous pulses the  
75 following equation applies for every two successive pulses:

$$76 \quad P_i = P_{i-1} SF_i, \quad i=1, \dots, N \quad (S8)$$

77 Where  $SF_i$  is the survival fraction after the i-th pulse of the N-pulse scheme.

78 The goal is to derive a suitable mathematical formulation of  $SF_i$ , so that the correct number of lethally  
79 hit cells is computed within CERONCO at the appropriate time points, just after each pulse dose.

80 (S7), (S8) =>

$$P_{init} \exp(-\alpha id - \beta i G_i d^2) = P_{init} \exp(-\alpha(i-1)d - \beta(i-1)G_{i-1} d^2) SF_i$$

$$81 \quad \Rightarrow SF_i = \frac{\exp(-\alpha id - \beta i G_i d^2)}{\exp[-\alpha(i-1)d - \beta(i-1)G_{i-1} d^2]}$$

82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113

$$\Rightarrow SF_i = \exp(-ad) \exp[-\beta d^2(iG_i - (i - 1)G_{i-1})], i=1...N \text{ (S9)}$$

Therefore, within CERONCO equation (S9) will be applied after each successive pulse.

$G_i$  is computed by Eq. (S2)-(S6) for  $N=i, \forall i \geq 2$ ,

and

$$G_1 = \frac{2 [\exp(-\mu t) + \mu t - 1]}{(\mu t)^2} \text{ (S10) for the first pulse}$$

(this is the appropriate equation for one dose of radiation delivered at constant dose rate during time interval  $t$  (5)). Eq. (S10) can be derived from Eq. (S2)-(S6) for  $N=1$  and  $x \rightarrow \infty$ .

Eq. (S9) is in essence a modification of the LQ model that can be used within CERONCO after each successive pulse and takes into account the current number of living tumour cells. This number is defined by the competing processes of cell death (due to radiotherapy, apoptosis, necrosis) and cell birth; these processes are incorporated in the cytokinetic model of Fig 1 of the main text.

In the pulsed brachytherapy scheme considered in the context of this study two brachytherapy fractions of 20 pulses each are used. The pulse dose is derived for each geometrical cell of the tumour mesh from the corresponding total dose distribution raw file by dividing the total dose corresponding to the specific geometrical cell by the number of pulses. The interval between successive pulses is 1 hour and the pulse duration varies among clinical cases (e.g. approximately 0.2-0.3 hours, i.e. time between pulses without irradiation: 0.8-0.7h).

114

115

## SUPPLEMENTARY MATERIAL SECTION SB:

116

117

### SB.1: THE CLINICAL DATA

118 Eight clinical cases of cervical cancer have been included in the study. The patients were treated as  
 119 part of the large prospective multicenter EMBRACE clinical study (6). Supplementary Table S1  
 120 presents a summary of the available clinical data. Follow-up data were not available. 01 provides a  
 121 schematic description of the evolution of the tumours' Gross Tumour Volume (GTV) throughout  
 122 therapy.

123 **Supplementary Table S1. Summarized description of basic features of the available patient cases.**

124 *SCC: Squamous cell carcinoma.*

125 *GTV: MRI-derived Gross Tumour Volume*

126 *EBRT: External Beam Radiotherapy*

127 *Pretherapy: Before start of treatment.*

128 *Day 0: pretherapy GTV based on MRI*

129 *Midterm: During EBRT*

130 *BT0: Before start of brachytherapy treatment*

131 *BT1: Start of 1<sup>st</sup> brachytherapy fraction*

132 *BT2: Start of 2<sup>nd</sup> brachytherapy fraction*

133 *NA: Not Available.*

134 *Initial equivalent diameter: the diameter of a sphere with the same volume as the actual initial tumour.*

135 *VRP: Volume Reduction Percentage,  $VRP = \left( \frac{GTV_{Pretherapy} - GTV_{Timepoint}}{GTV_{Timepoint}} \right) * 100\%$ ,*


136 *Timepoint  $\in$  {Midterm, BT0, BT1, BT2}*

137

	Clinical case							
	50	55	68	71	77	86	88	95
<b>Histology</b>	SCC	SCC	SCC	SCC	SCC	SCC	SCC	SCC
<b>FIGO stage</b>	4A	2B	2B	3B	2B	2B	2B	2B
<b>Differentiation degree</b>	NA	low	NA	low	NA	NA	NA	low
<b>Untreated time period (before EBRT start) (days)<sup>a</sup></b>	8	4	11	7	3	7	1	2
<b>EBRT</b>	45/25	45/25	50/30	50/30	45/25	45/25	45/25	50/30
<b>Total dose (Gy)/no of fractions</b>	Day 9 - Day 43	Day 5 - Day 41	Day 12 - Day 54	Day 8 - Day 54	Day 4 - Day 38	Day 8 - Day 42	Day 2- Day 38	Day 3- Day 31
<b>Duration<sup>a</sup></b>								

<b>No of cisplatin chemo cycles</b>	3 (2 lost)	5	6	6	5	5	5	5
<b>Chemotherapy schedule</b>	Weekly cisplatin 40mg/m <sup>2</sup> (1 <sup>st</sup> administration: start of EBRT)							
<b>PRETHERAPY MRI-derived GTV (mm<sup>3</sup>): (Equivalent diameter) (mm)</b>	22790 (35.18)	34352 (40.34)	11767 (28.22)	104633 (58.46)	27626 (37.5)	44131 (43.84)	46148 (46.15)	19466 (33.38)
<b>Necrosis diameter at pretherapy (mm)</b>	no	no	no	yes (18mm)	no	no	no	no
<b>MIDTERM MRI-derived GTV (mm<sup>3</sup>) [VRP (%) ]</b>	9201 [59.63]	8238 [76.02]	4157 [64.67]	24532 [76.55]	28556 [-3.37]	NA	21037 [54.41]	19440 [0.13]
<b>BT0 MRI-derived GTV (mm<sup>3</sup>) [VRP (%) ]</b>	9083 [60.14]	5300 [84.57]	1886 [83.97]	17968 [82.83]	6370 [76.94]	1009 [97.71]	2366 [94.87]	5138 [73.61]
<b>BT1 MRI-derived GTV (mm<sup>3</sup>) [VRP (%) ]</b>	8188 [64.07]	7913 [76.96]	2174 [81.52]	18719 [82.11]	6920 [74.95]	NA	3770 [91.83]	4463 [77.07]
<b>BT2 MRI-derived GTV (mm<sup>3</sup>): [VRP (%) ]</b>	8951 [60.72]	2097 [93.90]	415 [96.47]	13846 [86.77]	NA	NA	NA	3751 [80.73]
<b>Midterm<sup>a</sup></b>	Day 32	Day 22	Day 33	Day 29	Day 15	NA	Day 27	Day 15
<b>BT0<sup>a</sup></b>	Day 44	Day 41	Day 43	Day 46	Day 37	Day 36	Day 37	Day 42
<b>BT1<sup>a</sup></b>	Day 51 (20 pulses)	Day 48 (20 pulses)	Day 50 (20 pulses)	Day 50 (15 pulses)	Day 44 (20 pulses)	NA	Day 42 (20 pulses)	Day 49 (20 pulses)
<b>BT2<sup>a</sup></b>	Day 58 (20 pulses)	Day 54 (20 pulses)	Day 57 (20 pulses)	Day 57 (20 pulses)	NA	NA	NA	Day 56 (20 pulses)

139  
140



141  
142

143 **Supplementary Figure S1. Semilogarithmic plot of the Gross Tumour Volume (GTV) of the clinical cases at**  
144 **several timepoints.** Available timepoints: Pretherapy, Midterm (MID)(during EBRT), BT0 (Before BT start),  
145 BT1 (start of 1<sup>st</sup> BT fraction), BT2 (start of 2<sup>nd</sup> BT fraction). Day 0 corresponds to the day of acquisition of the  
146 pretherapy GTV. For the temporal features of each patients treatment schedule see Supplementary Table S1.  
147 Note: the lines connecting the GTV data points are provided to facilitate the understanding of the rate of tumour  
148 shrinkage in each case; they do not imply that tumour evolution over time in between the available GTV data  
149 points follows this linear pattern.

150

151

152

153

154

155

156

157

158

## SB.2: IMAGING DATA PREPROCESSING

159

160 Algorithms and code have been developed in order to transform the imaging data into a form  
161 appropriate to be used as an input to CERONCO. For each clinical case the following files are created  
162 as an input for CERONCO:

- 163 1) 3D-reconstructions of the Gross Tumour Volume (GTV) (raw files, tumour or non/tumour per  
164 GC) for (up to) 5 time points: Pretherapy (before start of treatment), Midterm (during external  
165 beam radiotherapy treatment), BT0 (before brachytherapy treatment), BT1 (start of 1<sup>st</sup>  
166 brachytherapy fraction), BT2 (start of 2<sup>nd</sup> brachytherapy fraction)  
167 2) BT1, BT2 spatial dose distribution raw files (dose per GC).

168 These 3D-reconstruction raw files supply the model with the tumour's spatial information and  
169 correspond to the region of interest onto which the discretizing mesh of the model is superimposed.  
170 Within each raw file each Geometrical Cell (GC) of the mesh is labeled as tumour or non/tumour. The  
171 procedure for the creation of these input files is the following:

- 172 • A Reference CT is acquired prior to therapy
- 173 • A Reference GTV is derived from the reference CT
- 174 • The MRI images of all available time points (pretherapy, mid-term, BT0, BT1, BT2) are  
175 registered to the reference CT.
- 176 • GTV files are derived from each MRI
- 177 • The MRI GTV files are registered to the Reference GTV (registration to the Reference GTV  
178 center of mass)
- 179 • The same procedure is used to produce the raw files for the BT doses

180

181 T2 weighted MRI with 4mm slice thickness was acquired according to the GEC ESTRO guidelines  
182 (7).

183

184

185

186

187

188

189



190

191

192

193

## SUPPLEMENTARY SECTION SC

194

195

### THE TUMOUR PROFILE CONCEPT

196 Supplementary Table S22 provides the mathematical relationships between tumour features (e.g.  
 197 Growth Fraction, GF, Hypoxic Fraction, HF, etc.) and CERONCO parameter values (8). The  
 198 computation of the various initial tumour cell populations is also explained. There is a number of  
 199 independent CERONCO parameters, randomly taking values within predefined ranges according to  
 200 literature; these are:  $T_C$ ,  $T_A$ , OER,  $R_A$ ,  $R_{ADiff}$ ,  $P_{G0toG1}$ ,  $P_{sym}$ ,  $\alpha$ , stem\_cell\_percentage. The dependent  
 201 parameters of the multi-constraint adaptation algorithm are the following:  $\beta$ ,  $P_{sleep}$ ,  $R_{NDiff}$ ,  $T_{G0}$ ,  $T_N$ ,  
 202  $N_{LIMP}$ ; the latter are computed based on the assigned values of the independent parameters and the  
 203 user-selected features of the tumour (see main text of the article: The tumour profile concept). NA:  
 204 non-applicable.

205 **Supplementary Table S2. Computation of CERONCO parameter values based on the chosen tumour**  
 206 **profile (GF, HF, DF) and the chosen value of the tumour's doubling time ( $T_d$ ).** For the description of  
 207 **the CERONCO parameters see Table 1 of the main article.**

208

Model parameter or virtual tumour feature	Description	Computation
<b>Total</b>	Initial total number of tumour cells	Computed based on the imaging-based GTV tumour volume, by considering a typical solid tumour cell density (e.g. $10^9$ cells/cm <sup>3</sup> ), unless more specific information for a particular tumour is available.
<b>DF (%)</b>	Initial tumour dead fraction (Percentage of dead tumour cells over all tumour cells).	<b><u>Defined by the user.</u></b> In the current study its estimation was based on the provided initial tumour's necrotic diameter.
<b>Dead</b>	Initial number of dead tumour cells.	Dead = DF*Total
<b>Living</b>	Initial number of living tumour cells.	Living= Total –Dead.
<b>HF (%)</b>	Hypoxic fraction. Percentage of hypoxic (dormant)	<b><u>Defined by the user.</u></b>

	tumour cells over all tumour cells.	
<b>Hypoxic</b>	Initial number of hypoxic (dormant) tumour cells.	Hypoxic = HF*Total
<b>GF (%)</b>	Growth fraction. Percentage of proliferating tumour cells over all living tumour cells.	<b>Defined by the user.</b>
<b>Prolif</b>	Initial number of proliferating tumour cells.	Prolif = GF*Living
<b>DIFF</b>	Initial number of terminally differentiated tumour cells.	DIFF =Living-Prolif-Hypoxic
<b>Stem_Cell_Percentage (%)</b>	Initial percentage of stem cells over all living tumour cells.	Random value $\in [0.01-0.12]$
<b>N<sub>S</sub></b>	Initial number of stem cells.	$N_S = \text{Stem\_Cell\_Percentage} * \text{Living}$
<b>N<sub>L</sub></b>	Initial number of LIMP cells.	$N_L = \text{Living}-\text{DIFF}-N_S$
<b>T<sub>d</sub> (days)</b>	Initial tumour volume doubling time.	<b>Defined by the user</b>
<b>r (h<sup>-1</sup>)</b>	Initial tumour growth rate.	$r = \ln(2)/T_d/24$
<b>CKR cisplatin</b>	Cisplatin Cell Kill Rate Fraction of stem and LIMP cells lethally hit at each drug administration .	<b>Defined by the user</b> $\in \{0.0, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5\}$
<b>T<sub>c</sub> (h)</b>	Cell cycle duration	Random value $\in [16- 70]$
<b>T<sub>A</sub> (h)</b>	Apoptosis duration	Random value $\in [1- 25]$
<b><math>\alpha</math> (Gy<sup>-1</sup>)</b>	Parameter of the LQ model	Random value $\in [0- 0.7]$
<b><math>\beta</math> (Gy<sup>-2</sup>)</b>	Parameter of the LQ model	Based on $\alpha$ value, so that $\alpha/ \beta=10\text{Gy}$
<b>OER</b>	Oxygen enhancement ratio	Random value $\in \{1.5, 2.0, 2.5, 3.0\}$
<b>R<sub>A</sub> (h<sup>-1</sup>)</b>	Spontaneous apoptosis rate of stem and	Random value $\in [0.001- 0.1]$ , step 0.001

	LIMP cells (fraction of stem and LIMP cells dying through spontaneous apoptosis per hour)	
$R_{ADiff} (h^{-1})$	Spontaneous apoptosis rate of differentiated cells (fraction of differentiated cells dying through spontaneous apoptosis per hour)	Random value $\in [0.001- 0.1]$ , step 0.001
$P_{G0toG1} (h^{-1})$	Fraction of dormant cells that re-enter cell cycle per hour	Random value $\in [0.01- 0.06]$ , step 0.01
$P_{sym}$	Fraction of stem cells at mitosis that perform symmetric division	Random value $\in [0.20- 0.66]$ , step 0.02
$T_{1/2} (h)$	Sublethal damage repair half-time	Fixed value =1.5
$T_{G0} (h)$	G0 duration	$T_{G0} = \left[ \frac{(1 + P_{sym} - e^{(r+R_A)*T_C}) * (r + R_A)}{(e^{(r+R_A)*T_C} - 1) * \frac{HF}{GF} \left( \frac{1}{1 - DF} \right)} - (r + R_A) \right]^{-1} * (1 - P_{G0toG1})$
$R_{NDiff} (h^{-1})$	Necrosis rate of differentiated cells (fraction of differentiated cells dying through necrosis per hour)	$R_{NDiff} = \frac{(1 - P_{sym}) * (r + R_A)}{(e^{(r+R_A)*T_C} - 1) * \frac{1}{GF} \left( 1 - \frac{1}{GF} - \frac{HF}{(1 - DF)} \right)} - r - R_{ADiff}$
$P_{sleep}$	Fraction of stem and LIMP cells entering G0 phase after mitosis	$P_{sleep} = \frac{1 - \frac{e^{(r+R_A)*T_C}}{1 + P_{sym}}}{1 - \frac{P_{G0toG1}}{T_{G0}} + \frac{1}{r + R_A + \frac{1}{T_{G0}}}}$

$T_N$ (h)	Necrosis duration	$T_N = \left[ \frac{\left( \frac{1 - P_{G0toG1}}{T_{G0}} * \frac{HF}{GF(1-DF)} + \frac{R_{NDiff}}{GF} * \left( 1 - \frac{1}{GF} - \frac{HF}{(1-DF)} \right) \right)}{\frac{Necrotic/Living}{GF}} \right]^{-1} - r$ <p>Where:</p> $\frac{Necrotic}{Living} = \frac{DF}{1-DF} - \frac{R_A}{r + \frac{1}{T_A}} * GF + \frac{R_A}{r + \frac{1}{T_A}} * \frac{HF}{1-DF} + \frac{R_{ADiff}}{r + \frac{1}{T_A}} * \left( 1 - GF - \frac{HF}{1-DF} \right)$ <p>Necrotic: Initial number of necrotic tumour cells.  Apoptotic: Initial number of apoptotic tumour cells.  Necrotic + Apoptotic = Dead</p>
$N_{LIMP}$	Number of LIMP (Limited Mitotic Potential) cell mitoses before terminal differentiation	<p>Computed so that:</p> $\sum_{n=0}^{N_{LIMP}-1} \frac{2^n}{(1 + P_{sym})^{n+1}} = \frac{1}{(1 - P_{sym}) * \frac{N_s}{N_L}}$

209

210

211

212

213

214

215

216

217

218

219

220

221

## SUPPLEMENTARY SECTION SD

222

223

### RESULTS

224 **Supplementary Table S3.** Number of solutions (model parameter value sets that result in agreement between  
 225 the virtual and the clinical tumours) identified for each patient case and tumour profile studied. GF: Growth  
 226 Fraction. HF: Hypoxic Fraction. DF: Dead cell fraction. CKR: cisplatin cell kill rate. For the definition of the  
 227 volumetric criteria see main text of the article. In this table solutions “VRP10” correspond only to those  
 228 solutions that do not belong to VRP5 or MIXED as well (i.e.  $5\% < |VRP_{simulated} - VRP_{clinical}| \leq 10\%$ ). For  
 229 patient 71 and tumour profile GF 60%, HF 30%, DF 5%, as well as for patient 88 and the tumour profile GF  
 230 10%, HF 30%, DF 5%, the simulations do not retrieve any solutions under the volumetric criteria studied.  
 231 These tumours seem to be incompatible with these specific tumour profiles.  
 232

TUMOUR PROFILE GF=60% HF=30% DF=5%								
Patient	Criterion	CKR 0.0	CKR 0.05	CKR 0.1	CKR 0.2	CKR 0.3	CKR 0.4	CKR 0.5
50	VRP 5	-	-	-	-	-	-	-
	VRP 10	-	-	-	-	7	5	-
	MIXED	-	-	-	-	11	34	-
	40% DV	-	-	-	14	110	98	10
	TOTAL (289)	-	-	-	14	128	137	10
55	VRP 5	-	-	-	-	-	-	-
	VRP 10	-	-	-	-	-	-	4
	MIXED	-	-	-	-	-	-	3
	40% DV	-	-	-	-	-	-	-
	TOTAL (7)	-	-	-	-	-	-	7
68	VRP 5	120	76	84	72	29	7	-
	VRP 10	256	157	143	127	71	12	-
	MIXED	909	716	747	808	726	274	19
	40% DV	-	-	-	-	-	-	-
	TOTAL (5353)	1285	949	974	1007	826	293	19
71	VRP 5	-	-	-	-	-	-	-
	VRP 10	-	-	-	-	-	-	-
	MIXED	-	-	-	-	-	-	-
	40% DV	-	-	-	-	-	-	-
	TOTAL (0)	-	-	-	-	-	-	-
77	VRP 5	14	17	15	14	22	5	-


	<b>VRP 10</b>	73	51	43	15	15	6	-
	<b>MIXED</b>	56	37	35	27	27	3	-
	<b>40% DV</b>	4	5	7	2	1	2	-
	<b>TOTAL (496)</b>	147	110	100	58	65	16	-
<b>86</b>	<b>VRP 5</b>	1715	1747	1777	1851	1656	1101	675
	<b>VRP 10</b>	64	71	36	48	22	9	4
	<b>MIXED</b>	-	-	-	-	-	-	-
	<b>40% DV</b>	-	-	-	-	-	-	-
	<b>TOTAL (10775)</b>	1779	1818	1813	1898	1678	1110	679
<b>88</b>	<b>VRP 5</b>	16	18	16	23	13	-	-
	<b>VRP 10</b>	2	2	-	-	-	-	-
	<b>MIXED</b>	51	41	30	29	33	-	-
	<b>40% DV</b>	-	-	1	-	-	-	-
	<b>TOTAL (275)</b>	69	61	47	52	46	-	-
<b>95</b>	<b>VRP 5</b>	-	-	-	-	-	1	2
	<b>VRP 10</b>	22	19	18	10	6	4	4
	<b>MIXED</b>	5	5	7	15	8	18	1
	<b>40% DV</b>	4	1	1	1	-	-	1
	<b>TOTAL (153)</b>	31	25	26	26	14	23	8
<b>TUMOUR PROFILE GF=10% HF=30% DF=5%</b>								
<b>Patient</b>	<b>Criterion</b>	<b>CKR 0.0</b>	<b>CKR 0.05</b>	<b>CKR 0.1</b>	<b>CKR 0.2</b>	<b>CKR 0.3</b>	<b>CKR 0.4</b>	<b>CKR 0.5</b>
<b>50</b>	<b>VRP 5</b>	-	-	-	-	40	5	2
	<b>VRP 10</b>	-	-	-	-	42	2	4
	<b>MIXED</b>	-	-	-	-	59	9	6
	<b>40% DV</b>	-	-	-	-	219	15	5
	<b>TOTAL (408)</b>	-	-	-	-	360	31	17
<b>55</b>	<b>VRP 5</b>	-	-	-	-	-	-	-
	<b>VRP 10</b>	-	-	-	-	5	-	-
	<b>MIXED</b>	-	-	-	-	-	-	-
	<b>40% DV</b>	-	-	-	-	-	-	-
	<b>TOTAL (5)</b>	-	-	-	-	5	-	-

68	VRP 5	-	-	1	-	-	-	-
	VRP 10	15	11	37	34	46	18	7
	MIXED	1133	1083	1136	1549	1490	320	116
	40% DV	-	-	-	-	-	-	-
	TOTAL (6996)	1148	1094	1174	1583	1536	338	123
71	VRP 5	-	-	1	-	3	1	-
	VRP 10	19	15	17	226	360	352	102
	MIXED	5	5	-	42	81	70	8
	40% DV	-	-	-	-	-	-	-
	TOTAL (1307)	24	20	18	268	444	423	110
77	VRP 5	-	-	-	-	-	-	-
	VRP 10	37	23	21	13	9	-	-
	MIXED	20	15	12	7	-	-	-
	40% DV	83	47	34	19	11	-	-
	TOTAL (351)	140	85	67	39	20	-	-
86	VRP 5	24	23	28	969	758	554	405
	VRP 10	-	-	-	478	396	288	198
	MIXED	-	-	-	-	-	-	-
	40% DV	-	-	-	-	-	-	-
	TOTAL (4121)	24	23	28	1447	1154	842	603
88	VRP 5	-	-	-	-	-	-	-
	VRP 10	-	-	-	-	-	-	-
	MIXED	-	-	-	-	-	-	-
	40% DV	-	-	-	-	-	-	-
	TOTAL (0)	-	-	-	-	-	-	-
95	VRP 5	6	10	9	8	6	-	-
	VRP 10	55	40	49	31	12	-	-
	MIXED	46	51	30	15	-	-	-
	40% DV	58	44	22	14	8	-	-
	TOTAL (514)	165	145	110	68	26	-	-
For patient 71 and tumour profile GF 60%, HF 30%, DF 5%, as well as for patient 88 and the tumour profile GF 10%, HF 30%, DF 5%, the simulations do not retrieve any solutions under the volumetric criteria studied. These tumours seem to be incompatible with these specific tumour profiles.								

233  
234

235

236



237

238

239

240 **Supplementary Figure S2.** Comparison of two different tumour scenarios, both compatible with the tumour  
241 volumetric data of patient 9, in terms of GTV and number of stem cells time course. Left panel: high  
242 proliferative profile. Right panel: low proliferative profile. The same value for the tumour cells'  
243 chemosensitivity to cisplatin was chosen for both cases ( $CKR=0.3$ ). The error bars indicate the permitted  
244 variability around the clinical VRP value according to the criteria VRP 10 (Eq. 11) and 40% DV (Eq. 13).

245

246

247

248

249

250

251

252

253

254



255 **Supplementary Table S4.** Tumour profile GF=10%, HF=30%, DF=5%, CKR: 0.0-0.5. Range of CERONCO parameter values from all identified solutions.  
 256 For the definition of CERONCO parameters see Table1 of the main article. For the computation of CERONCO parameter values based on the user-defined  
 257 tumour features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage  
 258 repair half-time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values represent the volume doubling time(s) of the virtual tumour(s) resulting from the mean value  
 259 parameter set(s).  
 260

GF 10% HF 30% DF 5%, CKR 0-0.5								
Range of CERONCO parameter values from all solutions								
Patient	50	55	68	71	77	86	88	95
No. of solutions	408	5	6997	1307	351	4121	0	514
$T_d$ (days)	20-4000	350-1000	20-4000	20-4000	20-200	20-4000		20-2500
$T_c$ (h)	16-28	39-41	16-48	16-50	16-50	16-36	-	16-53
$T_{G0}(h)$	88-439	246-290	81-439	97-439	119-435	81-439	-	108-439
$T_N$ (h)	6-47	19-32	6-67	6-34	6-65	6-62	-	6-74
$T_A$ (h)	1-25	11-25	1-25	1-25	1-25	1-25	-	1-25
$N_{LIMP}$	3-16	10-11	3-18	4-18	3-18	3-18	-	3-18
$\alpha$ ( $\text{Gy}^{-1}$ )	0.000-0.567	0.367-0.567	0.000-0.678	0.056-0.697	0.035-0.685	0.050-0.699	-	0.025-0.433
OER	1.5-3	1.5-3	1.5-3	1.5-3	1.5-3	1.5-3	-	1.5-3
$R_A$ ( $\text{h}^{-1}$ )	0.001-0.006	0.001	0.001-0.007	0.001-0.006	0.001-0.004	0.001-0.007	-	0.001-0.005
$R_{NDiff}$ ( $\text{h}^{-1}$ )	(06.7E-06)-0.0068	0.0004-0.0005	(3.9E-08)-0.0074	(5.4E-09)-0.002	(4.2E-07)-0.0047	(6.8E-07)-0.0075	-	(4.1E-06)-0.0058
$R_{ADiff}$ ( $\text{h}^{-1}$ )	0.001-0.007	0.001	0.001-0.008	0.001-0.002	0.001-0.005	0.001-0.008	-	0.001-0.005
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	0.01-0.06	0.02-0.05	0.01-0.06	0.01-0.06	0.01-0.06	0.01-0.06	-	0.01-0.06
$P_{sleep}$	0.165-0.394	0.369-0.385	0.153-0.410	0.266-0.402	0.192-0.390	0.153-0.410	-	0.182-0.384
$P_{sym}$	0.22-0.64	0.62-0.66	0.2-0.66	0.44-0.66	0.28-0.66	0.2-0.66	-	0.26-0.66

261  
 262  
 263

264 **Supplementary Table S5.** Tumour profile GF=10%, HF=30%, DF=5%, CKR=0.0. Mean value and range of values of each CERONCO parameter. For the  
 265 definition of CERONCO parameters see Table 1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 266 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 267 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
 268

GF 10% HF 30% DF 5%, CKR=0.0								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	0	0	1148	24	140	24	0	165
$T_d$ (days)	-	-	127 (20-4000)	176 (30-3000)	36 (20-200)	105 (20-4000)	-	44 (20-2500)
$T_c$ (h)	-	-	22 (16-44)	34 (21-45)	26 (16-50)	21 (16-35)	-	27 (16-53)
$T_{G0}$ (h)	-	-	253 (81-438)	285 (174-406)	302 (119-432)	266 (92-424)	-	298 (108-438)
$T_N$ (h)	-	-	16 (6-62)	14 (6-22)	25 (6-59)	15 (6-30)	-	25 (6-59)
$T_A$ (h)	-	-	10 (1-25)	9 (1-24)	12 (1-25)	11 (2-25)	-	12 (1-25)
$N_{LIMP}$ (no.)	-	-	8 (3-18)	11 (6-18)	9 (3-18)	7 (3-10)	-	9 (3-17)
$\alpha$ ( $\text{Gy}^{-1}$ )	-	-	0.084 (0.052-0.232)	0.362 (0.184-0.605)	0.204 (0.051-0.685)	0.388 (0.104-0.695)	-	0.109 (0.048-0.390)
OER	-	-	2.23 (1.5-3)	2.23 (1.5-3)	2.33 (1.5-3)	2.21 (1.5-3)	-	2.27 (1.5-3)
$R_A$ ( $\text{h}^{-1}$ )	-	-	0.0019 (0.001-0.007)	0.0013 (0.001-0.003)	0.0015 (0.001-0.004)	0.0018 (0.001-0.005)	-	0.0016 (0.001-0.005)
$R_{NDiff}$ ( $\text{h}^{-1}$ )	-	-	0.0019 ((2.8E-06)-0.0070)	0.00069 ((1.2E-05)-0.0012)	0.0099 ((1E-05)-0.0047)	0.0020 (0.00027-0.0043)	-	0.001 ((4.05E-06)-0.0058)
$R_{ADiff}$ ( $\text{h}^{-1}$ )	-	-	0.0021 (0.001-0.007)	0.0012 (0.001-0.002)	0.0015 (0.001-0.005)	0.0023 (0.001-0.005)	-	0.0014 (0.001-0.004)
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	-	-	0.035 (0.01-0.06)	0.035 (0.01-0.06)	0.038 (0.01-0.06)	0.038 (0.01-0.06)	-	0.038 (0.01-0.06)
$P_{sleep}$	-	-	0.301 (0.154-0.410)	0.345 (0.285-0.395)	0.314 (0.192-0.389)	0.288 (0.194-0.386)	-	0.318 (0.183-0.384)
$P_{sym}$	-	-	0.485 (0.2-0.66)	0.584 (0.46-0.66)	0.534 (0.28-0.66)	0.451 (0.26-0.62)	-	0.542 (0.26-0.66)

269  
 270  
 271

272

273 **Supplementary Table S6.** Tumour profile GF=10%, HF=30%, DF=5%, CKR=0.05. Mean value and range of values of each CERONCO parameter. For  
 274 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 275 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 276 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
 277

GF 10% HF 30% DF 5%, CKR=0.05								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	0	0	1094	20	85	23	0	145
$T_d$ (days)	-	-	127 (20-4000)	301 (20-4000)	29 (20-90)	81 (30-4000)	-	30 (20-400)
$T_c$ (h)	-	-	22 (16-44)	35 (21-48)	24 (16-44)	21 (16-33)	-	24 (16-51)
$T_{G0}$ (h)	-	-	254 (81-439)	297 (168-392)	295 (139-439)	245 (107-422)	-	288 (125-438)
$T_N$ (h)	-	-	16 (6-62)	16 (6-30)	26 (7-64)	14 (6-38)	-	23 (6-55)
$T_A$ (h)	-	-	10 (1-25)	9 (1-22)	11 (1-23)	11 (1-24)	-	12 (1-25)
$N_{LIMP}$ (no.)	-	-	8 (3-18)	10 (6-18)	9 (4-17)	7 (3-11)	-	9 (4-18)
$\alpha$ ( $\text{Gy}^{-1}$ )	-	-	0.077 (0.046-0.265)	0.410 (0.145-0.688)	0.175 (0.052-0.635)	0.396 (0.121-0.679)	-	0.109 (0.045-0.433)
OER	-	-	2.24 (1.5-3)	2.00 (1.5-3)	2.19 (1.5-3)	2.11 (1.5-3)	-	2.25 (1.5-3)
$R_A$ ( $\text{h}^{-1}$ )	-	-	0.0019 (0.001-0.007)	0.0015 (0.001-0.004)	0.0014 (0.001-0.004)	0.0013 (0.001-0.003)	-	0.0017 (0.001-0.004)
$R_{NDiff}$ ( $\text{h}^{-1}$ )	-	-	0.0019 ((2.8E-06)-0.0070)	0.00057 ((3.1E-05)-0.0011)	0.00099 ((1.1E-06)-0.0042)	0.0029 ((5.9E-05)-0.0065)	-	0.001((1.6E-05)-0.0049)
$R_{ADiff}$ ( $\text{h}^{-1}$ )	-	-	0.0022 (0.001-0.007)	0.0012 (0.001-0.002)	0.0014 (0.001-0.004)	0.0017 (0.001-0.005)	-	0.0015 (0.001-0.005)
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	-	-	0.035 (0.01-0.06)	0.033 (0.01-0.06)	0.038 (0.01-0.06)	0.036 (0.01-0.06)	-	0.035 (0.01-0.06)
$P_{sleep}$	-	-	0.301 (0.154-0.410)	0.348 (0.315-0.398)	0.313 (0.213-0.383)	0.280 (0.185-0.368)	-	0.311 (0.182-0.381)
$P_{sym}$	-	-	0.485 (0.2-0.66)	0.599 (0.52-0.66)	0.540 (0.32-0.66)	0.424 (0.24-0.64)	-	0.533 (0.26-0.66)

278  
 279  
 280  
 281

282 **Supplementary Table S7.** Tumour profile GF=10%, HF=30%, DF=5%, CKR=0.1. Mean value and range of values of each CERONCO parameter. For the  
 283 definition of CERONCO parameters see Table 1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 284 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 285 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
 286

GF 10% HF 30% DF 5%, CKR=0.1								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No.of solutions	0	0	1174	18	67	28	0	110
$T_d$ (days)	-	-	102 (20-4000)	318 (50-3000)	25 (20-50)	166 (50-4000)	-	23 (20-80)
$T_c$ (h)	-	-	22 (16-48)	35 (22-46)	24 (16-38)	21 (16-30)	-	22 (16-41)
$T_{G0}$ (h)	-	-	255 (84-439)	286 (164-389)	320 (171-432)	249 (115-396)	-	296 (143-439)
$T_N$ (h)	-	-	16 (6-67)	12 (6-23)	26 (7-65)	12 (6-36)	-	23 (6-74)
$T_A$ (h)	-	-	10 (1-25)	11 (1-23)	12 (1-24)	11 (1-23)	-	12 (1-25)
$N_{LIMP}$ (no.)	-	-	8 (3-18)	9 (6-13)	9 (4-18)	9 (4-16)	-	9 (4-17)
$\alpha$ ( $\text{Gy}^{-1}$ )	-	-	0.072 (0.040-0.304)	0.342 (0.123-0.652)	0.195 (0.061-0.668)	0.335 (0.093-0.697)	-	0.101 (0.038-0.390)
OER	-	-	2.26 (1.5-3)	2.08 (1.5-3)	2.36 (1.5-3)	2.20 (1.5-3)	-	2.18 (1.5-3)
$R_A$ ( $\text{h}^{-1}$ )	-	-	0.0019 (0.001-0.006)	0.0014 (0.001-0.003)	0.0017 (0.001-0.004)	0.0019 (0.001-0.004)	-	0.0017 (0.001-0.005)
$R_{NDiff}$ ( $\text{h}^{-1}$ )	-	-	0.0019 ((3.9E-08)-0.0074)	0.00064 ((8.7E-06)-0.001)	0.0010 ((8.6E-06)-0.0045)	0.0025 ((5.6E-05)-0.0053)	-	0.0011 ((9.6E-06)-0.0041)
$R_{ADiff}$ ( $\text{h}^{-1}$ )	-	-	0.0021 (0.001-0.007)	0.0012 (0.001-0.002)	0.0014 (0.001-0.003)	0.0019 (0.001-0.004)	-	0.0015 (0.001-0.005)
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	-	-	0.035 (0.01-0.06)	0.037 (0.01-0.06)	0.036 (0.01-0.06)	0.032 (0.01-0.06)	-	0.035 (0.01-0.06)
$P_{sleep}$	-	-	0.301 (0.153-0.408)	0.351 (0.315-0.391)	0.304 (0.203-0.390)	0.293 (0.168-0.368)	-	0.305 (0.211-0.379)
$P_{sym}$	-	-	0.485 (0.2-0.66)	0.602 (0.52-0.66)	0.524 (0.3-0.66)	0.465 (0.22-0.64)	-	0.524 (0.3-0.66)

287

288

289 **Supplementary Table S8.** Tumour profile GF=10%, HF=30%, DF=5%, CKR=0.2. Mean value and range of values of each CERONCO parameter. For the  
 290 definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 291 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations The sublethal damage repair half-  
 292 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
 293

GF 10% HF 30% DF 5%, CKR=0.2								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	0	0	1583	268	39	1447	0	68
$T_d$ (days)	-	-	99 (20-4000)	185 (20-3000)	22 (20-30)	83 (20-4000)	-	20 (20-30)
$T_c$ (h)	-	-	22 (16-46)	34 (17-50)	23 (16-29)	20 (16-36)	-	21 (16-34)
$T_{G0}$ (h)	-	-	252 (81-439)	293 (116-438)	314 (150-435)	255 (81-439)	-	328 (144-437)
$T_N$ (h)	-	-	16 (6-57)	13 (6-34)	25 (7-44)	14 (6-62)	-	24 (6-52)
$T_A$ (h)	-	-	10 (1-25)	10 (1-24)	12 (1-25)	10 (1-25)	-	12 (1-25)
$N_{LIMP}$ (no.)	-	-	8 (3-18)	10 (5-18)	9 (5-17)	7 (3-18)	-	8 (3-13)
$\alpha$ ( $\text{Gy}^{-1}$ )	-	-	0.061 (0.024-0.678)	0.407 (0.067-0.697)	0.189 (0.047-0.675)	0.402 (0.054-0.699)	-	0.086 (0.031-0.390)
OER	-	-	2.24 (1.5-3)	2.24 (1.5-3)	2.14 (1.5-3)	2.24 (1.5-3)	-	2.35 (1.5-3)
$R_A$ ( $\text{h}^{-1}$ )	-	-	0.0019 (0.001-0.007)	0.0014 (0.001-0.004)	0.0016 (0.001-0.004)	0.0019 (0.001-0.007)	-	0.0016 (0.001-0.005)
$R_{NDiff}$ ( $\text{h}^{-1}$ )	-	-	0.0018((2.9E-06)-0.0071)	0.00069 ((1.4E-06)-0.002)	0.00086 ((4.2E-07)-0.0029)	0.0022 ((4.4E-06)-0.0069)	-	0.0013 ((8.6E-06)-0.0049)
$R_{ADiff}$ ( $\text{h}^{-1}$ )	-	-	0.0019 (0.001-0.008)	0.0011 (0.001-0.002)	0.0016 (0.001-0.004)	0.0023 (0.001-0.008)	-	0.0015 (0.001-0.003)
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	-	-	0.035 (0.01-0.06)	0.034 (0.01-0.06)	0.035 (0.01-0.06)	0.035 (0.01-0.06)	-	0.037 (0.01-0.06)
$P_{sleep}$	-	-	0.302 (0.153-0.410)	0.344 (0.267-0.398)	0.304 (0.200-0.374)	0.288 (0.154-0.410)	-	0.285 (0.191-0.371)
$P_{sym}$	-	-	0.489 (0.2-0.66)	0.589 (0.44-0.66)	0.526 (0.3-0.66)	0.457 (0.2-0.66)	-	0.483 (0.28-0.66)

294

295

296 **Supplementary Table S9.** Tumour profile GF=10%, HF=30%, DF=5%, CKR=0.3. Mean value and range of values of each CERONCO parameter. For the  
 297 definition of CERONCO parameters see Table 1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 298 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 299 time  $T_{1/2}$  is taken equal to 1.5Gy. Td values displayed as: value resulting from the mean value parameter set (range of Td in all solutions).  
 300

GF 10% HF 30% DF 5%, CKR=0.3								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	360	5	1536	444	20	1154	0	26
T <sub>d</sub> (days)	98 (20-4000)	450 (350-1000)	97 (20-4000)	154 (20-4000)	20 ((20)	79 (20-4000)		20 (20)
T <sub>c</sub> (h)	18 (16-25)	39 (39-41)	22 (16-45)	34 (16-49)	23 (17-28)	20 (16-35)	-	24 (19-28)
T <sub>G0</sub> (h)	254 (92-438)	261 (246-290)	253 (84-439)	289 (97-439)	313 (144-427)	253 (85-439)	-	342 (189-437)
T <sub>N</sub> (h)	12 (6-35)	22 (19-32)	16 (6-66)	13 (6-32)	29 (10-52)	14 (6-60)	-	29 (8-52)
T <sub>A</sub> (h)	9 (1-25)	21 (11-25)	10 (1-25)	10 (1-24)	12 (2-25)	10 (1-25)	-	12 (2-25)
N <sub>LIMP</sub> (no.)	6 (3-16)	10 (10-11)	8 (3-18)	10 (5-18)	8 (6-13)	7(3-18)	-	8 (5-12)
$\alpha$ (Gy <sup>-1</sup> )	0.007 (0.0-0.567)	0.510 (0.367-0.567)	0.042 (0.008-0.619)	0.469 (0.060-0.619)	0.182 (0.035-0.505)	0.335 (0.052-0.567)	-	0.106 (0.025-0.390)
OER	2.21 (1.5-3)	2.20 (1.5-3)	2.25 (1.5-3)	2.19 (1.5-3)	2.33 (1.5-3)	2.26 (1.5-3)	-	2.40 (1.5-3)
R <sub>A</sub> (h <sup>-1</sup> )	0.0018 (0.001-0.006)	0.001 (0.001)	0.0019 (0.001-0.007)	0.0014 (0.001-0.005)	0.0012 (0.001-0.003)	0.0019 (0.001-0.007)	-	0.0012 (0.001-0.003)
R <sub>NDiff</sub> (h <sup>-1</sup> )	0.0028 ((6.7E-06)-0.0068)	0.00046 (0.0004-0.0005)	0.0018 ((1.3E-06)-0.0073)	0.00068 ((1.2E-06)-0.002)	0.00077 ((8.6E-06)-0.0034)	0.0023 ((6.8E-07)-0.0075)	-	0.00082 ((8.6E-06)-0.0034)
R <sub>ADiff</sub> (h <sup>-1</sup> )	0.0027 (0.001-0.007)	0.001 (0.001)	0.0020 (0.001-0.008)	0.0011 (0.001-0.002)	0.0014 (0.001-0.003)	0.0022 (0.001-0.007)	-	0.0013 (0.001-0.003)
P <sub>G0toG1</sub> (h <sup>-1</sup> )	0.035 (0.01-0.06)	0.04 (0.02-0.05)	0.034 (0.01-0.06)	0.035 (0.01-0.06)	0.035 (0.34-0.64)	0.035 (0.01-0.06)	-	0.036 (0.01-0.06)
P <sub>sleep</sub>	0.263 (0.165-0.378)	0.378 (0.369-0.385)	0.304 (0.154-0.402)	0.347 (0.266-0.398)	0.300 (0.219-0.371)	0.288 (0.153-0.406)	-	0.293 (0.219-0.357)
P <sub>sym</sub>	0.399 (0.22-0.64)	0.644 (0.62-0.66)	0.494 (0.2-0.66)	0.594 (0.44-0.66)	0.509 (0.34-0.64)	0.454 (0.2-0.66)	-	0.498 (0.34-0.66)

301  
302

303

304 **Supplementary Table S10.** Tumour profile GF=10%, HF=30%, DF=5%, CKR=0.4. Mean value and range of values of each CERONCO parameter. For  
 305 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 306 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 307 time  $T_{1/2}$  is taken equal to 1.5Gy. Td values displayed as: value resulting from the mean value parameter set (range of Td in all solutions).  
 308

GF 10% HF 30% DF 5%, CKR=0.4								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	31	0	338	423	0	842	0	0
T <sub>d</sub> (days)	28 (20-80)	-	42 (20-1000)	175 (20-4000)	-	87 (20-4000)	-	-
T <sub>c</sub> (h)	19 (16-28)	-	21 (16-38)	34 (16-50)	-	20 (16-34)	-	-
T <sub>G0</sub> (h)	277 (88-439)	-	255 (92-439)	300 (117-437)	-	248 (82-439)	-	-
T <sub>N</sub> (h)	18 (6-47)	-	16 (6-51)	14 (6-34)	-	14 (6-61)	-	-
T <sub>A</sub> (h)	8 (1-20)	-	11 (1-25)	9 (1-25)	-	10 (1-25)	-	-
N <sub>LIMP</sub> (no.)	7 (3-14)	-	8 (3-18)	10 (4-18)	-	7 (3-18)	-	-
$\alpha$ (Gy <sup>-1</sup> )	0.057 (0-0.431)	-	0.062 (0-0.471)	0.374 (0.056-0.471)	-	0.254 (0.050-0.431)	-	-
OER	2.18 (1.5-3)	-	2.25 (1.5-3)	2.23 (1.5-3)	-	2.25 (1.5-3)	-	-
R <sub>A</sub> (h <sup>-1</sup> )	0.0013 (0.001-0.003)	-	0.0018 (0.001-0.007)	0.0014 (0.001-0.006)	-	0.0019 (0.001-0.006)	-	-
R <sub>NDiff</sub> (h <sup>-1</sup> )	0.0020 ((9.1E-06)-0.0058)	-	0.0017 ((9.1E-06)-0.0065)	0.00065 ((1.2E-06)-0.001)	-	0.0021 ((2.2E-06)-0.0073)	-	-
R <sub>ADiff</sub> (h <sup>-1</sup> )	0.0027 (0.001-0.006)	-	0.0018 (0.001-0.007)	0.0011 (0.001-0.002)	-	0.0023 (0.001-0.008)	-	-
P <sub>G0toG1</sub> (h <sup>-1</sup> )	0.037 (0.01-0.06)	-	0.035 (0.01-0.06)	0.035 (0.01-0.06)	-	0.036 (0.01-0.06)	-	-
P <sub>sleep</sub>	0.265 (0.184-0.394)	-	0.303 (0.174-0.401)	0.344 (0.266-0.402)	-	0.291 (0.156-0.406)	-	-
P <sub>sym</sub>	0.409 (0.26-0.64)	-	0.500 (0.24-0.66)	0.590 (0.44-0.66)	-	0.461 (0.2-0.66)	-	-

309  
 310  
 311  
 312

313 **Supplementary Table S11.** Tumour profile GF=10%, HF=30%, DF=5%, CKR=0.5. Mean value and range of values of each CERONCO parameter. For  
 314 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 315 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 316 time  $T_{1/2}$  is taken equal to 1.5Gy. Td values displayed as: value resulting from the mean value parameter set (range of Td in all solutions).  
 317

GF 10% HF 30% DF 5%, CKR=0.5								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	17	0	123	110	0	603	0	0
T <sub>d</sub> (days)	20 (20-30)	-	28 (20-600)	40 (20-150)	-	84 (20-4000)	-	-
T <sub>c</sub> (h)	17 (16-25)	-	20 (16-46)	26 (16-41)	-	20 (16-34)	-	-
T <sub>G0</sub> (h)	286 (172-438)	-	235 (91-437)	273 (108-438)	-	251 (86-436)	-	-
T <sub>N</sub> (h)	16 (6-41)	-	16 (6-52)	12 (6-23)	-	14 (6-57)	-	-
T <sub>A</sub> (h)	11 (1-23)	-	11 (1-25)	9 (1-23)	-	10 (1-25)	-	-
N <sub>LIMP</sub> (no.)	6 (3-10)	-	9 (3-16)	9 (5-18)	-	7 (3-18)	-	-
$\alpha$ (Gy <sup>-1</sup> )	0.032 (0.002-0.326)	-	0.083 (0-0.357)	0.315 (0.066-0.357)	-	0.197 (0.050-0.326)	-	-
OER	2.21 (1.5-3)	-	2.20 (1.5-3)	2.28 (1.5-3)	-	2.22 (1.5-3)	-	-
R <sub>A</sub> (h <sup>-1</sup> )	0.0012 (0.001-0.002)	-	0.0018 (0.001-0.005)	0.0017 (0.001-0.004)	-	0.0019 (0.001-0.007)	-	-
R <sub>NDiff</sub> (h <sup>-1</sup> )	0.0024 ((7.8E-06)-0.0049)	-	0.0015 ((8.6E-06)-0.0058)	0.00079 ((5.4E-09)-0.002)	-	0.0022 ((7.7E-07)-0.0075)	-	-
R <sub>ADiff</sub> (h <sup>-1</sup> )	0.0022 (0.001-0.005)	-	0.0016 (0.001-0.004)	0.0012 (0.001-0.002)	-	0.0023 (0.001-0.007)	-	-
P <sub>G0toG1</sub> (h <sup>-1</sup> )	0.029 (0.01-0.06)	-	0.037 (0.01-0.06)	0.036 (0.01-0.06)	-	0.035 (0.01-0.06)	-	-
P <sub>sleep</sub>	0.251 (0.201-0.358)	-	0.312 (0.183-0.399)	0.330 (0.267-0.389)	-	0.287 (0.157-0.401)	-	-
P <sub>sym</sub>	0.392 (0.3-0.62)	-	0.523 (0.26-0.66)	0.572 (0.44-0.66)	-	0.453 (0.2-0.66)	-	-

318  
 319  
 320



321 **Supplementary Table S12.** Tumour profile GF=10%, HF=30%, DF=5%, CKR: 0.0-0.5. Range of mean values of each CERONCO parameter (from  
322 Supplementary Tables S5-S10). For the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter  
323 values based on the user-defined tumour features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all  
324 simulations. The sublethal damage repair half-time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values represent the volume doubling time(s) of the virtual tumour(s)  
325 resulting from the mean value parameter set(s).  
326

GF 10% HF 30% DF 5%, CKR 0-0.5								
Range of mean values of CERONCO parameters in the mean value sets, CKR 0-0.5								
Patient	50	55	68	71	77	86	88	95
$T_d$ (days)	20-98	450	28-127	40-318	20-36	79-166	-	20-44
$T_c$ (h)	17-19	39	20-22	26-35	23-26	20-21	-	21-27
$T_{G0}$ (h)	254-286	261	235-255	273-300	295-320	245-266	-	288-342
$T_N$ (h)	12-18	22	16	12-16	25-29	12-15	-	23-29
$T_A$ (h)	8-11	21	10-11	9-11	11-12	10-11	-	12
$N_{LIMP}$ (no.)	6-7	10	8-9	9-11	8-9	7-9	-	8-9
$\alpha$ ( $\text{Gy}^{-1}$ )	0.007-0.057	0.510	0.042-0.084	0.315-0.469	0.175-0.204	0.197-0.402	-	0.086-0.109
OER	2.18-2.21	2.20	2.20-2.26	2-2.28	2.12-2.36	2.11-2.26	-	2.18-2.40
$R_A$ ( $\text{h}^{-1}$ )	0.001-0.002	0.001	0.002	0.001-0.002	0.001-0.002	0.0013-0.0019	-	0.001-0.002
$R_{NDiff}$ ( $\text{h}^{-1}$ )	0.002-0.003	0.0005	0.002	0.0006-0.002	0.001	0.0020-0.0029	-	0.001
$R_{ADiff}$ ( $\text{h}^{-1}$ )	0.001-0.003	0.001	0.002	0.001	0.001	0.0017-0.0023	-	0.001-0.002
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	0.029-0.037	0.040	0.034-0.037	0.033-0.037	0.035-0.038	0.032-0.038	-	0.035-0.038
$P_{sleep}$	0.251-0.265	0.378	0.301-0.312	0.330-0.351	0.300-0.314	0.280-0.293	-	0.285-0.318
$P_{sym}$	0.392-0.409	0.644	0.485-0.523	0.572-0.602	0.509-0.540	0.424-0.465	-	0.483-0.542

327  
328  
329

330 **Supplementary Table S13.** Tumour profile GF=60%, HF=30%, DF=5%, CKR: 0.0-0.5 Range of CERONCO parameter values from all identified  
 331 solutions. For the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-  
 332 defined tumour features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal  
 333 damage repair half-time  $T_{1/2}$  is taken equal to 1.5Gy. Td values represent the volume doubling time(s) of the virtual tumour(s) resulting from the mean  
 334 value parameter set(s).  
 335

GF 60% HF 30% DF 5%, CKR 0-0.5								
Range of CERONCO parameter values from all solutions								
Patient	50	55	68	71	77	86	88	95
No. of solutions	289	7	5353	0	496	10775	275	153
T <sub>d</sub> (days)	20-250	20	20-1500	-	20-50	20-2000	20-200	20-50
T <sub>c</sub> (h)	27-70	38-50	26-70	-	26-70	25-70	39-70	35-70
T <sub>G0</sub> (h)	67-433	61-111	61-439	-	74-439	61-439	113-438	132-439
T <sub>N</sub> (h)	6-28	6-7	6-25	-	6-28	6-37	6-48	6-45
T <sub>A</sub> (h)	1-16	1-6	1-19	-	1-23	1-19	1-25	1-19
N <sub>LIMP</sub> (no.)	5-18	12-15	4-18	-	5-18	4-18	5-18	5-18
$\alpha$ (Gy <sup>-1</sup> )	0.004-0.042	0.002-0.037	0.000-0.149	-	0.038-0.103	0.050-0.699	0.050-0.165	0.036-0.071
OER	1.5-3	1.5-3	1.5-3	-	1.5-3	1.5-3	1.5-3	1.5-3
R <sub>A</sub> (h <sup>-1</sup> )	0.001-0.01	0.001-0.002	0.001-0.01	-	0.001-0.008	0.001-0.011	0.001-0.004	0.001-0.005
R <sub>NDiff</sub> (h <sup>-1</sup> )	0.004-0.236	0.068-0.141	0.0015-0.249	-	0.006-0.242	(1.7E-05)-0.257	0.002-0.237	0.002-0.209
R <sub>ADiff</sub> (h <sup>-1</sup> )	0.001-0.1	0.019-0.071	0.001-0.1	-	0.001-0.1	0.001-0.1	0.001-0.1	0.001-0.1
P <sub>G0toG1</sub> (h <sup>-1</sup> )	0.01-0.06	0.01-0.05	0.01-0.06	-	0.01-0.06	0.01-0.06	0.01-0.06	0.01-0.06
P <sub>sleep</sub>	0.125-0.334	0.256-0.328	0.110-0.369	-	0.125-0.318	0.108-0.377	0.128-0.273	0.119-0.270
P <sub>sym</sub>	0.24-0.6	0.54-0.66	0.2-0.66	-	0.26-0.66	0.2-0.66	0.24-0.66	0.24-0.66

336  
 337  
 338

339 **Supplementary Table S14.** Tumour profile GF=60%, HF=30%, DF=5%, CKR=0.0. Mean value and range of values of each CERONCO parameter. For  
 340 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 341 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 342 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
 343

GF 60% HF 30% DF 5%, CKR=0.0								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	0	0	1285	0	147	1779	69	31
$T_d$ (days)	-	-	100 (20-1500)	-	28 (20-50)	66 (20-1000)	20 (20-200)	33 (20-50)
$T_c$ (h)	-	-	56 (28-70)	-	55 (26-70)	57 (25-70)	60 (39-70)	62 (54-70)
$T_{G0}$ (h)	-	-	175 (61-439)	-	197 (74-404)	197 (62-439)	364 (113-431)	268 (132-438)
$T_N$ (h)	-	-	8 (6-25)	-	8 (6-28)	8 (6-37)	11 (6-48)	8 (6-23)
$T_A$ (h)	-	-	3 (1-17)	-	4 (1-14)	4 (1-19)	6 (1-16)	5 (1-10)
$N_{LIMP}$ (no.)	-	-	11 (4-18)	-	11 (5-18)	11 (4-18)	12 (6-18)	9 (5-18)
$\alpha$ ( $\text{Gy}^{-1}$ )	-	-	0.064 (0.040-0.141)	-	0.064 (0.043-0.103)	0.280 (0.055-0.499)	0.109 (0.050-0.165)	0.048 (0.039-0.063)
OER	-	-	2.24 (1.5-3)	-	2.26 (1.5-3)	2.27 (1.5-3)	2.26 (1.5-3)	2.33 (1.5-3)
$R_A$ ( $\text{h}^{-1}$ )	-	-	0.0025 (0.001-0.01)	-	0.0021 (0.001-0.008)	0.0024 (0.001-0.011)	0.0016 (0.001-0.004)	0.0015 (0.001-0.003)
$R_{NDiff}$ ( $\text{h}^{-1}$ )	-	-	0.103 (0.003-0.246)	-	0.106 (0.006-0.215)	0.105 ((1.69E-05)-0.257)	0.093 (0.002-0.237)	0.111 (0.009-0.209)
$R_{ADiff}$ ( $\text{h}^{-1}$ )	-	-	0.051 (0.001-0.1)	-	0.049 (0.001-0.1)	0.050 (0.001-0.1)	0.041 (0.001-0.1)	0.053 (0.005-0.094)
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	-	-	0.036 (0.01-0.06)	-	0.036 (0.01-0.06)	0.035 (0.01-0.06)	0.038 (0.01-0.06)	0.040 (0.01-0.06)
$P_{sleep}$	-	-	0.236 (0.113-0.369)	-	0.218 (0.127-0.318)	0.225 (0.110-0.372)	0.179 (0.132-0.273)	0.193 (0.119-0.270)
$P_{sym}$	-	-	0.517 (0.2-0.66)	-	0.517 (0.26-0.66)	0.508 (0.2-0.66)	0.528 (0.24-0.66)	0.429 (0.24-0.62)

344  
 345  
 346  
 347

348 **Supplementary Table S15.** Tumour profile GF=60%, HF=30%, DF=5%, CKR=0.05. Mean value and range of values of each CERONCO parameter. For  
349 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
350 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
351 time  $T_{1/2}$  is taken equal to 1.5Gy. Td values displayed as: value resulting from the mean value parameter set (range of Td in all solutions).  
352

GF 60% HF 30% DF 5%, CKR=0.05 (For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	0	0	949	0	110	1818	61	25
T <sub>d</sub> (days)	-	-	68 (20-400)	-	23 (20-50)	61 (20-1000)	20 (20-150)	26 (20-45)
T <sub>c</sub> (h)	-	-	55 (26-70)	-	54 (26-70)	57 (25-70)	59 (39-70)	60 (45-69)
T <sub>G0</sub> (h)	-	-	180 (66-438)	-	226 (81-439)	198 (62-439)	374 (179-434)	304 (140-434)
T <sub>N</sub> (h)	-	-	8 (6-20)	-	8 (6-24)	8 (6-37)	9 (6-25)	11 (6-45)
T <sub>A</sub> (h)	-	-	3 (1-14)	-	4 (1-14)	4 (1-19)	7 (1-20)	4 (1-9)
N <sub>LIMP</sub> (no.)	-	-	11 (5-18)	-	11 (5-18)	11 (4-18)	11 (5-18)	9 (5-16)
$\alpha$ (Gy <sup>-1</sup> )	-	-	0.062 (0.036-0.149)	-	0.064 (0.042-0.103)	0.278 (0.062-0.499)	0.107 (0.058-0.168)	0.047 (0.037-0.059)
OER	-	-	2.25 (1.5-3)	-	2.27 (1.5-3)	2.27 (1.5-3)	2.21 (1.5-3)	2.31 (1.5-3)
R <sub>A</sub> (h <sup>-1</sup> )	-	-	0.0025 (0.001-0.1)	-	0.0022 (0.001-0.008)	0.0024 (0.001-0.011)	0.0013 (0.001-0.003)	0.0018 (0.001-0.003)
R <sub>NDiff</sub> (h <sup>-1</sup> )	-	-	0.107 (0.002-0.249)	-	0.115 (0.021-0.242)	0.106 ((1.7E-05)-0.253)	0.101 (0.005-0.237)	0.079 (0.002-0.163)
R <sub>ADiff</sub> (h <sup>-1</sup> )	-	-	0.050 (0.001-0.1)	-	0.047 (0.003-0.1)	0.050 (0.001-0.1)	0.046 (0.001-0.1)	0.047 (0.002-0.099)
P <sub>G0toG1</sub> (h <sup>-1</sup> )	-	-	0.034 (0.01-0.06)	-	0.035 (0.01-0.06)	0.035 (0.01-0.06)	0.035 (0.01-0.06)	0.035 (0.01-0.06)
P <sub>sleep</sub>	-	-	0.230 (0.110-0.366)	-	0.206 (0.125-0.303)	0.225 (0.110-0.372)	0.172 (0.128-0.236)	0.175 (0.127-0.260)
P <sub>sym</sub>	-	-	0.516 (0.2-0.66)	-	0.509 (0.26-0.66)	0.508 (0.2-0.66)	0.496 (0.24-0.66)	0.430 (0.28-0.64)

353  
354  
355  
356

357 **Supplementary Table S16.** Tumour profile GF=60%, HF=30%, DF=5%, CKR=0.1. Mean value and range of values of each CERONCO parameter. For  
358 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
359 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
360 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
361

GF 60% HF 30% DF 5%, CKR=0.1									
(For each parameter: mean value (range))									
Patient	50	55	68	71	77	86	88	95	
No. of solutions	0	0	974	0	100	1813	47	26	
$T_d$ (days)	-	-	71 (20-400)	-	20 (20-35)	55 (20-1000)	20 (20-40)	22 (20-35)	
$T_c$ (h)	-	-	55 (26-70)	-	52 (26-70)	56 (27-70)	61 (44-70)	61 (44-70)	
$T_{G0}$ (h)	-	-	182 (65-438)	-	216 (74-439)	197 (62-439)	386 (325-438)	292 (139-429)	
$T_N$ (h)	-	-	8 (6-19)	-	8 (6-25)	8 (6-28)	12 (6-28)	11 (6-28)	
$T_A$ (h)	-	-	3 (1-14)	-	4 (1-14)	4 (1-19)	6 (1-17)	5 (1-16)	
$N_{LIMP}$ (no.)	-	-	11 (5-18)	-	12 (5-18)	11 (5-18)	12 (7-18)	11 (5-16)	
$\alpha$ ( $\text{Gy}^{-1}$ )	-	-	0.054 (0.029-0.142)	-	0.065 (0.044-0.094)	0.377 (0.059-0.699)	0.104 (0.059-0.146)	0.049 (0.036-0.069)	
OER	-	-	2.27 (1.5-3)	-	2.24 (1.5-3)	2.27 (1.5-3)	2.22 (1.5-3)	2.40 (1.5-3)	
$R_A$ ( $\text{h}^{-1}$ )	-	-	0.0025 (0.001-0.01)	-	0.0024 (0.001-0.008)	0.002 (0.001-0.01)	0.0013 (0.001-0.003)	0.0016 (0.001-0.005)	
$R_{NDiff}$ ( $\text{h}^{-1}$ )	-	-	0.107 (0.002-0.249)	-	0.102 (0.019-0.213)	0.105 (0.001-0.254)	0.079 (0.004-0.157)	0.098 (0.005-0.225)	
$R_{ADiff}$ ( $\text{h}^{-1}$ )	-	-	0.050 (0.001-0.1)	-	0.051 (0.001-0.1)	0.050 (0.001-0.1)	0.051 (0.004-0.096)	0.054 (0.004-0.1)	
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	-	-	0.035 (0.01-0.06)	-	0.035 (0.01-0.06)	0.035 (0.01-0.06)	0.034 (0.01-0.06)	0.044 (0.01-0.06)	
$P_{sleep}$	-	-	0.230 (0.110-0.367)	-	0.213 (0.125-0.303)	0.226 (0.108-0.376)	0.177 (0.148-0.205)	0.191 (0.128-0.256)	
$P_{sym}$	-	-	0.515 (0.2-0.66)	-	0.551 (0.28-0.66)	0.512 (0.2-0.66)	0.529 (0.34-0.66)	0.474 (0.28-0.62)	

362  
363  
364

365  
366  
367  
368  
369  
370

**Supplementary Table S17. Tumour profile GF=60%, HF=30%, DF=5%, CKR=0.2. Mean value and range of values of each CERONCO parameter. For the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulation. The sublethal damage repair half-time  $T_{1/2}$  is taken equal to 1.5Gy. Td values displayed as: value resulting from the mean value parameter set (range of Td in all solutions).**

GF 60% HF 30% DF 5%, CKR=0.2 (For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	14	0	1007	0	58	1898	52	26
T <sub>d</sub> (days)	189 (100-250)	-	71 (20-400)	-	20 (20)	50 (20-1000)	20 (20)	20 (20)
T <sub>c</sub> (h)	54 (37-66)	-	56 (27-70)	-	50 (33-68)	56 (26-70)	58 (42-70)	59 (47-70)
T <sub>G0</sub> (h)	189 (79-326)	-	184 (66-438)	-	212 (74-430)	200 (62-439)	384 (316-436)	285 (142-413)
T <sub>N</sub> (h)	6 (6-8)	-	8 (6-20)	-	8 (6-18)	8 (6-28)	12 (6-43)	10 (6-19)
T <sub>A</sub> (h)	3 (1-7)	-	3 (1-19)	-	5 (1-15)	4 (1-19)	8 (1-25)	6 (1-19)
N <sub>LIMP</sub> (no.)	9 (6-16)	-	11 (5-18)	-	12 (6-18)	11 (5-18)	12 (8-17)	12 (7-17)
$\alpha$ (Gy <sup>-1</sup> )	0.011 (0.009-0.015)	-	0.039 (0.014-0.127)	-	0.064 (0.044-0.086)	0.373 (0.050-0.699)	0.105 (0.054-0.142)	0.051 (0.040-0.057)
OER	2.18 (1.5-3)	-	2.26 (1.5-3)	-	2.21 (1.5-3)	2.27 (1.5-3)	2.24 (1.5-3)	2.22 (1.5-3)
R <sub>A</sub> (h <sup>-1</sup> )	0.0026 (0.001-0.007)	-	0.0025 (0.001-0.01)	-	0.0017 (0.001-0.004)	0.002 (0.001-0.01)	0.001 (0.001-0.002)	0.0015 (0.001-0.003)
R <sub>N<sup>Diff</sup></sub> (h <sup>-1</sup> )	0.136 (0.049-0.226)	-	0.106 (0.0015-0.249)	-	0.119 (0.025-0.226)	0.106 (0.002-0.254)	0.092 (0.003-0.201)	0.093 (0.015-0.205)
R <sub>A<sup>Diff</sup></sub> (h <sup>-1</sup> )	0.047 (0.008-0.085)	-	0.049 (0.001-0.1)	-	0.047 (0.002-0.094)	0.050 (0.001-0.1)	0.040 (0.001-0.1)	0.045 (0.001-0.1)
P <sub>G<sub>0</sub>toG<sub>1</sub></sub> (h <sup>-1</sup> )	0.029 (0.01-0.06)	-	0.035 (0.01-0.06)	-	0.039 (0.01-0.06)	0.035 (0.01-0.06)	0.032 (0.01-0.06)	0.040 (0.01-0.06)
P <sub>sleep</sub>	0.214 (0.145-0.318)	-	0.229 (0.108-0.366)	-	0.205 (0.146-0.293)	0.224 (0.110-0.372)	0.177 (0.145-0.201)	0.198 (0.144-0.269)
P <sub>sym</sub>	0.450 (0.24-0.6)	-	0.514 (0.2-0.66)	-	0.526 (0.36-0.66)	0.511 (0.2-0.66)	0.548 (0.36-0.66)	0.527 (0.36-0.66)

371  
372  
373

374 **Supplementary Table S18. Tumour profile GF=60%, HF=30%, DF=5%, CKR=0.3. Mean value and range of values of each CERONCO parameter. For**  
 375 **the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour**  
 376 **features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-**  
 377 **time  $T_{1/2}$  is taken equal to 1.5Gy. Td values displayed as: value resulting from the mean value parameter set (range of Td in all solutions).**  
 378

GF 60% HF 30% DF 5%, CKR=0.3								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	128	0	826	0	65	1678	46	14
T <sub>d</sub> (days)	51 (30-100)		55 (20-250)	-	20 (20)	52 (20-2000)	20 (20)	20 (20)
T <sub>c</sub> (h)	57 (27-70)	-	56 (27-70)	-	49 (35-63)	56 (27-70)	58 (42-70)	51 (40-63)
T <sub>G0</sub> (h)	188 (67-433)	-	188 (66-438)	-	218 (117-428)	200 (62-439)	384 (333-436)	286 (183-426)
T <sub>N</sub> (h)	8 (6-18)	-	8 (6-20)	-	8 (6-19)	8 (6-28)	13 (6-43)	8 (6-11)
T <sub>A</sub> (h)	4 (1-10)	-	4 (1-19)	-	5 (1-20)	3 (1-19)	10 (1-25)	6 (1-17)
N <sub>LIMP</sub> (no.)	11 (5-18)	-	11 (5-18)	-	13 (6-18)	11 (5-18)	13 (8-18)	12 (7-17)
$\alpha$ (Gy <sup>-1</sup> )	0.014 (0.004-0.024)	-	0.024 (0.001-0.100)	-	0.060 (0.043-0.075)	0.311 (0.050-0.637)	0.092 (0.064-0.121)	0.054 (0.049-0.059)
OER	2.29 (1.5-3)	-	2.26 (1.5-3)	-	2.34 (1.5-3)	2.26 (1.5-3)	2.34 (1.5-3)	2.39 (1.5-3)
R <sub>A</sub> (h <sup>-1</sup> )	0.0023 (0.001-0.01)	-	0.0024 (0.001-0.01)	-	0.0017 (0.001-0.004)	0.0024 (0.001-0.1)	0.0010 (0.001-0.002)	0.0015 (0.001-0.002)
R <sub>NDiff</sub> (h <sup>-1</sup> )	0.101 (0.004-0.236)	-	0.107 (0.004-0.242)	-	0.108 (0.019-0.237)	0.106 (0.002-0.254)	0.086 (0.003-0.201)	0.124 (0.022-0.180)
R <sub>ADiff</sub> (h <sup>-1</sup> )	0.052 (0.001-0.099)	-	0.048 (0.001-0.1)	-	0.041 (0.001-0.096)	0.050 (0.001-0.1)	0.035 (0.001-0.1)	0.045 (0.002-0.098)
P <sub>G0toG1</sub> (h <sup>-1</sup> )	0.035 (0.01-0.06)	-	0.034 (0.01-0.06)	-	0.041 (0.01-0.06)	0.035 (0.01-0.06)	0.033 (0.01-0.06)	0.037 (0.01-0.06)
P <sub>sleep</sub>	0.227 (0.125-0.334)	-	0.227 (0.110-0.366)	-	0.207 (0.140-0.263)	0.224 (0.110-0.377)	0.182 (0.153-0.205)	0.183 (0.146-0.237)
P <sub>sym</sub>	0.516 (0.24-0.66)	-	0.513 (0.2-0.66)	-	0.571 (0.34-0.66)	0.510 (0.2-0.66)	0.579 (0.44-0.66)	0.514 (0.4-0.66)

379  
380

381

382 **Supplementary Table S19.** Tumour profile GF=60%, HF=30%, DF=5%, CKR=0.4. Mean value and range of values of each CERONCO parameter. For  
 383 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 384 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 385 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
 386

	GF 60% HF 30% DF 5%, CKR=0.4							
	(For each parameter: mean value (range))							
Patient	50	55	68	71	77	86	88	95
No. of solutions	137	0	293	0	16	1110	-	23
$T_d$ (days)	24 (20-35)	-	29 (20-40)	-	20 (20)	45 (20-1000)	-	20 (20)
$T_c$ (h)	58 (36-70)	-	55 (29-70)	-	52 (37-64)	56 (28-70)	-	53 (35-67)
$T_{G0}$ (h)	217 (78-428)	-	190 (69-438)	-	262 (135-408)	203 (62-439)	-	331 (155-439)
$T_N$ (h)	9 (6-28)	-	8 (6-24)	-	9 (6-14)	8 (6-25)	-	12 (6-27)
$T_A$ (h)	4 (1-16)	-	4 (1-19)	-	7 (2-23)	4 (1-19)	-	5 (1-19)
$N_{LIMP}$ (no.)	12 (5-18)	-	12 (5-18)	-	14 (8-18)	11 (5-18)	-	13 (7-17)
$\alpha$ ( $\text{Gy}^{-1}$ )	0.016 (0.006-0.034)	-	0.020 (0-0.075)	-	0.048 (0.038-0.060)	0.245 (0.05-0.431)	-	0.054 (0.038-0.071)
OER	2.22 (1.5-3)	-	2.24 (1.5-3)	-	2.14 (1.5-3)	2.28 (1.5-3)	-	2.39 (1.5-3)
$R_A$ ( $\text{h}^{-1}$ )	0.0019 (0.001-0.005)	-	0.0022 (0.001-0.009)	-	0.0015 (0.001-0.003)	0.0023 (0.001-0.009)	-	0.0013 (0.001-0.004)
$R_{NDiff}$ ( $\text{h}^{-1}$ )	0.100 (0.005-0.215)	-	0.110 (0.010-0.242)	-	0.077 (0.015-0.220)	0.106 (0.002-0.253)	-	0.093 (0.019-0.182)
$R_{ADiff}$ ( $\text{h}^{-1}$ )	0.046 (0.001-0.1)	-	0.045 (0.001-0.1)	-	0.059 (0.005-0.097)	0.050 (0.001-0.1)	-	0.048 (0.008-0.091)
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	0.037 (0.01-0.06)	-	0.035 (0.01-0.06)	-	0.041 (0.01-0.06)	0.035 (0.01-0.06)	-	0.033 (0.01-0.06)
$P_{sleep}$	0.217 (0.128-0.321)	-	0.223 (0.130-0.340)	-	0.204 (0.152-0.256)	0.222 (0.110-0.368)	-	0.184 (0.148-0.224)
$P_{sym}$	0.523 (0.28-0.66)	-	0.523 (0.28-0.66)	-	0.589 (0.48-0.66)	0.513 (0.2-0.66)	-	0.563 (0.44-0.66)

387  
 388  
 389



390 **Supplementary Table S20.** Tumour profile GF=60%, HF=30%, DF=5%, CKR=0.5. Mean value and range of values of each CERONCO parameter. For  
 391 the definition of CERONCO parameters see Table1 of main article. For the computation of CERONCO parameter values based on the user-defined tumour  
 392 features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations. The sublethal damage repair half-  
 393 time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values displayed as: value resulting from the mean value parameter set (range of  $T_d$  in all solutions).  
 394

GF 60% HF 30% DF 5%, CKR=0.5								
(For each parameter: mean value (range))								
Patient	50	55	68	71	77	86	88	95
No. of solutions	10	7	19	0	0	679	0	8
$T_d$ (days)	20 (20)	20 (20)	20 (20)	-	-	46 (20-1000)	-	20 (20)
$T_c$ (h)	58 (43-67)	45 (38-50)	52 (30-70)	-	-	57 (26-70)	-	46 (40-51)
$T_{G0}$ (h)	387 (313-433)	94 (61-111)	169 (99-258)	-	-	193 (61-439)	-	378 (338-425)
$T_N$ (h)	12 (6-21)	6 (6-7)	7 (6-9)	-	-	8 (6-36)	-	9 (6-15)
$T_A$ (h)	5 (1-10)	3 (1-6)	7 (1-17)	-	-	4 (1-19)	-	5 (1-9)
$N_{LIMP}$ (no.)	11 (7-17)	14 (12-15)	13(8-18)	-	-	12 (4-18)	-	13 (9-17)
$\alpha$ ( $\text{Gy}^{-1}$ )	0.036 (0.026-0.042)	0.014 (0.002-0.037)	0.012 (0.003-0.036)	-	-	0.168 (0.05-0.281)	-	0.054 (0.047-0.059)
OER	2.7 (1.5-3)	2.07 (1.5-3)	2.26 (1.5-3)	-	-	2.25 (1.5-3)	-	2.07 (1.5-3)
$R_A$ ( $\text{h}^{-1}$ )	0.0013 (0.001-0.002)	0.0014 (0.001-0.002)	0.0017 (0.001-0.005)	-	-	0.0023 (0.001-0.009)	-	0.0016 (0.001-0.002)
$R_{NDiff}$ ( $\text{h}^{-1}$ )	0.088 (0.030-0.202)	0.113 (0.068-0.141)	0.104 (0.039-0.164)	-	-	0.101 (0.001-0.219)	-	0.103 (0.034-0.180)
$R_{ADiff}$ ( $\text{h}^{-1}$ )	0.054 (0.007-0.082)	0.041 (0.019-0.071)	0.043 (0.001-0.096)	-	-	0.050 (0.001-0.1)	-	0.055 (0.011-0.099)
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	0.036 (0.01-0.06)	0.034 (0.01-0.05)	0.031 (0.01-0.06)	-	-	0.035 (0.01-0.06)	-	0.031 (0.01-0.06)
$P_{sleep}$	0.172 (0.147-0.190)	0.271 (0.256-0.328)	0.227 (0.168-0.300)	-	-	0.229 (0.112-0.367)	-	0.171 (0.160-0.179)
$P_{sym}$	0.514 (0.38-0.62)	0.600 (0.54-0.66)	0.564 (0.44-0.66)	-	-	0.521 (0.2-0.66)	-	0.560 (0.52-0.62)

395  
 396  
 397

398

399 **Supplementary Table S21.** Tumour profile GF=60%, HF=30%, DF=5%, CKR: 0.0-0.5. Range of mean values of each CERONCO parameter (from  
400 Supplementary Tables S5-S10). For the definition of CERONCO parameters see Table 1 of main article. For the computation of CERONCO parameter values  
401 based on the user-defined tumour features see Supplementary Table S2. The  $\beta$  parameter of the LQ model is chosen so that  $\alpha/\beta=10\text{Gy}$  in all simulations.  
402 The sublethal damage repair half-time  $T_{1/2}$  is taken equal to 1.5Gy.  $T_d$  values represent the volume doubling time(s) of the virtual tumour(s) resulting from  
403 the mean value parameter set(s).

404  
405  
406

GF 60% HF 30% DF 5%, CKR 0-0.5								
Range of mean values of CERONCO parameters in the mean value sets, CKR 0-0.5								
Patient	50	55	68	71	77	86	88	95
$T_d$ (days)	20-51	20	20-100	-	20-28	45-66	20	20-33
$T_c$ (h)	54-58	45	52-56	-	49-55	56-57	58-61	46-62
$T_{G0}$ (h)	188-387	94	169-190	-	197-262	193-203	364-386	268-378
$T_N$ (h)	6-12	6	7-8	-	8-9	8	9-13	8-12
$T_A$ (h)	3-5	3	3-7	-	4-7	3-4	6-10	4-6
$N_{LIMP}$ (no.)	9-12	14	11-13	-	11-14	11-12	11-13	9-13
$\alpha$ ( $\text{Gy}^{-1}$ )	0.011-0.036	0.014	0.012-0.064	-	0.048-0.065	0.168-0.377	0.092-0.109	0.047-0.054
OER	2.18-2.7	2.07	2.24-2.27	-	2.14-2.34	2.25-2.28	2.21-2.34	2.07-2.40
$R_A$ ( $\text{h}^{-1}$ )	0.0013-0.0026	0.0014	0.0017-0.0025	-	0.0015-0.0024	0.002-0.0024	0.001-0.0016	0.0013-0.0018
$R_{NDiff}$ ( $\text{h}^{-1}$ )	0.088-0.136	0.113	0.103-0.110	-	0.077-0.119	0.101-0.106	0.079-0.101	0.079-0.124
$R_{ADiff}$ ( $\text{h}^{-1}$ )	0.046-0.054	0.041	0.043-0.051	-	0.041-0.059	0.050	0.035-0.051	0.045-0.055
$P_{G0toG1}$ ( $\text{h}^{-1}$ )	0.029-0.037	0.034	0.031-0.036	-	0.035-0.041	0.035	0.032-0.038	0.031-0.044
$P_{sleep}$	0.172-0.227	0.271	0.223-0.236	-	0.204-0.218	0.222-0.229	0.172-0.182	0.171-0.198
$P_{sym}$	0.450-0.523	0.600	0.513-0.564	-	0.509-0.589	0.508-0.521	0.496-0.579	0.429-0.563

407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441

## SUPPLEMENTARY MATERIAL REFERENCES

1. Brenner, D. J., Dale, R., Orton, C., Fowler, J. Radiobiology of high dose-rate, low dose-rate, and pulsed dose-rate brachytherapy. In *Principles and Practice of Brachytherapy* (eds. Flynn, A. et al.). p. 189-204 (Arnold, 2001).
2. Pötter, R. et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 78, 67–77 (2006).
3. Polo, A. Pulsed dose rate brachytherapy. *Clin Transl Oncol* 10, 324–333 (2008).
4. De Leeuw, A. A. C., Van de Kamer, J. B., Moerland, M. A., Philippens, M. E. P. & Jürgenliemk-Schulz, I.-M. The effect of alternative biological modelling parameters ( $\alpha/\beta$  and half time of repair  $T_{1/2}$ ) on reported EQD2 values in the treatment of advanced cervical cancer. *Radiotherapy and Oncology* 101, 337–342 (2011).
5. Carlson, D. J., Stewart, R. D. & Semenenko, V. A. Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters. *Med Phys* 33, 3105–3115 (2006).
6. Tanderup, K. et al. 54 speaker EMBRACE UPDATE. *Radiotherapy and Oncology* 99, S22–S23 (2011).
7. Dimopoulos, J. C. A. et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. *Radiother Oncol* 103, 113–122 (2012).
8. Kolokotroni, E. et al. In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model. *PLoS Comput. Biol.* 12, e1005093 (2016).